MedTrace Logo

Effects of Developmental Support for Mothers of Infants With Spinal Muscular Atrophy

NCT07547189 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2026-07-09

No results posted yet for this study

Summary

Spinal muscular atrophy (SMA) is an autosomal recessive neurodegenerative disorder causing progressive muscle weakness and atrophy. This mixed-methods study aims to provide developmental support to mothers of infants (aged 12-36 months) with SMA Type 1 and to evaluate its impact on infants' developmental outcomes and mothers' developmental knowledge.

Participants included eight mothers of infants/children diagnosed with SMA Type 1 who were recruited through purposive sampling from a university hospital. Quantitative data were collected using a General Information Form, the Ages and Stages Questionnaires (ASQ), the Ages and Stages Questionnaires: Social-Emotional (ASQ-SE), and the Caregiver Knowledge of Child Development Inventory (CKCDI). Qualitative data were obtained through semi-structured interviews exploring mothers' experiences with the developmental support program.

The intervention consisted of a 12-week online developmental support program delivered once a week for 90 minutes. Outcome assessments were conducted at baseline, immediately after the intervention, and four weeks after the intervention (follow-up assessment) to evaluate the sustainability of the intervention effects.

Conditions

Interventions

BEHAVIORAL

Online Early Intervention Program for Infants with SMA Type 1

A 12-week online early intervention program designed and implemented by the researcher for mothers of infants/children diagnosed with SMA Type 1. Conducted once a week for 90 minutes, the program provided education and guidance to support children's overall development, enhance mothers' developmental knowledge, and promote family-centered developmental practices. Post-intervention assessments were conducted immediately after completion of the program, followed by a follow-up assessment four weeks later.

Sponsors & Collaborators

  • Istanbul Medipol University Hospital

    collaborator OTHER

  • Medipol University

    lead OTHER

Principal Investigators

  • Aysil S TOGUR, MSc · Ankara University

Study Design

Allocation
NA
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
12 Months
Max Age
36 Months
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-04-08
Primary Completion
2026-06-03
Completion
2026-07-03

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07547189 on ClinicalTrials.gov